Skip To Main Content
Markus Magerl on Muck Rack

Markus Magerl

As seen in: Allergy - European Journal of Allergy and Clinical Immunology, Color Research & Application, Wiley Online Library, Clinical and Translational Allergy, World Allergy Organization Journal, The Lancet, HCP Live, The Journal of Allergy & Clinical Immunology, EMJ- European Medical Journal, Value in Health Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Markus

Contact Markus, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PCR66 LONG-TERM PROPHYLACTIC TREATMENT WITH ORAL DEUCRICTIBANT IMPROVED DISEASE CONTROL AND HEALTH-RELATED QUALITY OF LIFE IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA: FINAL RESULTS OF THE CHAPTER-1 OPEN-LABEL EXTENSION STUDY

|
By Michael Manning, Immunology Associates, John Anderson, Francesco Arcoleo, Mauro Cancian, Hugo Chapdelaine, Niall Conlon, Efrem Eren, Mark Gompels, Sofia Grigoriadou, Padmalal Gurugama, Tamar Kinaciyan, Markus Magerl, Marcin Stobiecki, Maria D. Guarino, Sorena Kiani
| Value in Health Journal Verified
1Allergy, Asthma and Immunology Associates, Ltd., Scottsdale, AZ, USA 2AllerVie Health, Clinical Research Center of Alabama, Birmingham, AL, USA 3AOR Villa Sofia-Cervello, UOC di Patologia Clinica e Immunologia, Palermo, Italy 4Azienda Ospedale Università di Padova, Padua, Italy 5CHU de Montréal, Université de Montréal, Montréal, QC, Canada 6St. James's Hospital and Trinity College, Wellcome Trust CRF, Dublin, Ireland 7University Hospital Southampton NHS Foundation Trust, Southampton, United...
Open in Who Shared Issue with article?

HAE in 2026: New Therapies, Updated Guidelines, the Case for Early Treatment

|
By Mauro Cancian, Markus Magerl, Aleena Banerji
| consultantlive.com
The treatment landscape for hereditary angioedema is undergoing one of its most significant evolutions in years. Updated international guidelines, pivotal phase 3 data, and promising early-phase results are collectively reshaping how clinicians approach both prophylaxis and acute management of this rare, potentially life-threatening condition. Three experts recently spoke with HCPLive about where the field stands and where it is headed.
Open in Who Shared View Duplicates (2) Issue with article?

BW-20805 Reduces HAE Attacks in Phase 2 Trial, With Markus Magerl, MD

|
By Markus Magerl
| consultantlive.com
Late-breaking data presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in Philadelphia suggest that BW-20805, an investigational therapy designed to suppress plasma prekallikrein production through a targeted RNA interference approach, may offer long-acting prophylaxis for patients with hereditary angioedema (HAE).
Open in Who Shared View Duplicates (2) Issue with article?
See all 20 licensed articles (28 Total)